There are currently 1881 clinical trials in Philadelphia, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pennsylvania, Children's Hospital of Philadelphia, Fox Chase Cancer Center and Thomas Jefferson University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07032662
Recruiting
This is a Phase 2b study to evaluate the efficacy and safety of IMVT-1402 in adults with CIDP.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Site Number - 1616, Philadelphia, Pennsylvania
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Register for Updates
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
NCT05589714
Recruiting
This is an international, multicenter study with two components: Registry * A standardized genetic screening and a prospective, standardized, cross-sectional clinical data collection * Enrollment is open to all genes on the RD Rare Gene List Natural History Study * A prospective, standardized, longitudinal Natural History Study * Enrollment opens gene-by-gene, based on funding and within-gene Registry enrollment The study objectives are as follows. Registry Objectives 1. Genotype Character... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
06/16/2025
Locations: Center for Advanced Retinal and Ocular Therapeutics, Philadelphia, Pennsylvania +1 locations
Conditions: Inherited Retinal Degeneration, Retinitis Pigmentosa
Register for Updates
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
NCT05646381
Recruiting
The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
06/16/2025
Locations: Perelman School of Medicine, Philadelphia, Pennsylvania
Conditions: Aortic Stenosis
Register for Updates
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
NCT05024929
Recruiting
Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become available. While Investigators know that these drugs shrink DTC tumors in many cases, the impact on radioactive iodine (RAI) avidity has not been systematically studied.
Gender:
ALL
Ages:
0 years and above
Trial Updated:
06/16/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Papillary Thyroid Cancer, Pediatric Cancer, Differentiated Thyroid Cancer
Register for Updates
A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"
NCT06374797
Recruiting
Approximately 150 patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF) will be randomized at up to 40 sites. Patients will be randomly assigned to either Auxora or matching placebo. Study drug infusions will occur every 24 hours for five consecutive days for a total of five infusions.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Temple University, Philadelphia, Pennsylvania
Conditions: Acute Kidney Injury
Register for Updates
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
NCT05742802
Recruiting
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.
Gender:
ALL
Ages:
Between 40 years and 130 years
Trial Updated:
06/16/2025
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118
Recruiting
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and ol... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/16/2025
Locations: Paddington Testing Company- Site Number : 8401041, Philadelphia, Pennsylvania +1 locations
Conditions: Dermatitis Atopic
Register for Updates
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)
NCT06264180
Recruiting
This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/16/2025
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania +1 locations
Conditions: Advanced Melanoma
Register for Updates
Robotic-Assisted da Vinci System Prophylactic Nipple-Sparing Mastectomy
NCT03892980
Recruiting
This study evaluates the safety and effectiveness of the da Vinci Surgical Systems in prophylactic Nipple Sparing Mastectomy procedures.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
06/16/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Nipple Sparing Mastectomy
Register for Updates
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
NCT04561518
Recruiting
The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
Gender:
ALL
Ages:
All
Trial Updated:
06/16/2025
Locations: Clinical Trial Site, Philadelphia, Pennsylvania
Conditions: Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis
Register for Updates
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
NCT04674969
Recruiting
The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Hospital University of Pennsylvania, Philadelphia, Pennsylvania +1 locations
Conditions: Peripheral Vascular Diseases
Register for Updates
StrokeNet Thrombectomy Endovascular Platform
NCT06289985
Recruiting
STEP is a Randomized, Multifactorial, Adaptive Platform trial that seeks to optimize the care of patients with acute ischemic stroke (AIS) due to large (LVO) or medium vessel occlusions (MVO).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Ischemic Stroke
Register for Updates